Paradigm Biopharmaceuticals (CRYPTO: PAR) — Company Overview, News & Financial Data
Paradigm Biopharmaceuticals is an Australian biotech company developing treatments for osteoarthritis using iPPS.
Paradigm Biopharmaceuticals
Paradigm Biopharmaceuticals is a clinical-stage biopharmaceutical company focused on repurposing existing, approved medications to address unmet medical needs. Established in 2014 and headquartered in Melbourne, Australia, the company repurposes drugs with established safety profiles, primarily using injectable pentosan polysulfate sodium. Its lead late-stage clinical candidate, Zilosul, is undergoing Phase 3 trials as a novel, non-opioid, disease-modifying treatment for pain and functional impairment associated with knee osteoarthritis. Beyond osteoarthritis, Paradigm develops therapies for rare disease indications such as mucopolysaccharidosis, as well as inflammatory arthritis, respiratory, and cardiovascular conditions.
Snapshot
Operations
Products and/or services of Paradigm Biopharmaceuticals
- Knee Osteoarthritis Therapeutics: Development of injectable pentosan polysulfate sodium as a subcutaneous, non-opioid therapy for moderate to severe knee osteoarthritis pain, supported by Phase 3 clinical evaluation across 65 trial sites in Australia, the United States, Hong Kong, and Moldova.
- Rare Lysosomal Storage Disease Therapeutics: Clinical research and drug development evaluating injectable pentosan polysulfate sodium for lysosomal storage diseases, specifically targeting mucopolysaccharidosis types to reduce pain, inflammation, and mobility impairment in pediatric and adult patient populations globally.
- Inflammatory Arthritis Therapeutics: Exploratory and clinical pipeline programs evaluating pentosan polysulfate sodium applications for inflammatory joint diseases, aiming to mitigate chronic joint pain, cartilage degradation, and systemic inflammatory responses in autoimmune and degenerative musculoskeletal disorders.
- Respiratory Disease Therapeutics: Investigational therapeutic research applying polysulfated glycans to inflammatory respiratory conditions, addressing unmet treatment needs in chronic airway inflammation and pulmonary disease models through targeted anti-inflammatory mechanisms.
- Cardiovascular Indication Therapeutics: Early-stage biopharmaceutical research evaluating pentosan polysulfate sodium formulations for vascular and cardiovascular inflammatory pathologies, focusing on endothelial protection and reducing vascular inflammation across targeted patient cohorts.
- Drug Supply and Manufacturing Infrastructure: Establishment of commercial-scale drug manufacturing partnerships and supply chain pathways for polysulfated glycan active pharmaceutical ingredients, ensuring scalability, quality control, and continuity of supply for global clinical trials and future commercial distribution.
Paradigm Biopharmaceuticals executive team
- Mr. Paul John Rennie BSc, Grad Dip, MBM, MSTCFounder, MD & Executive Chairman
- Dr. Donna L. Skerrett M.D., MSChief Medical Officer and Executive Director
- Ms. Abby Macnish Niven B.Com., B.Sc., C.F.A.Interim Company Secretary & Interim CFO
- Dr. Ravi KrishnanChief Scientific Officer
- Mr. Simon WhiteDirector of Investor Relations
- Dr. Michael ImperialeGlobal Head of Drug Safety & MPS
- Ms. Beverley HuttmannCommercial Head
- Ms. Michelle CoffeyGlobal Head of Regulatory Affairs
- Dr. Mukesh AhujaGlobal Clinical Head of OA